TABLE A2.
Province-specific drug coverage and PLA use (QC, NB, NS, PEI, NL)
| Drug | Indication | QC | NB | NS | PEI | NL |
|---|---|---|---|---|---|---|
| Aripiprazole | Schizophrenia and related disorders | Listed without PLA | Listed without PLA | Listed without PLA | Not listed | Listed without PLA |
| Azelaic acid | Rosacea | Listed without PLA | Not listed | Listed without PLA | Not listed | Listed without PLA |
| Aztreonam for Inhalation Solution | Cystic fibrosis | Not listed | Under review | Listed without PLA | Not listed | Listed without PLA |
| Brinzolamide and timolol maleate susp. | Glaucoma and ocular hypertension | Listed without PLA | Listed without PLA | Listed without PLA | Listed without PLA | Listed without PLA |
| Calcitriol | Psoriasis | Listed without PLA | Not listed | Not listed | Not listed | Not listed |
| Canakinumab | Cryopyrin-associated periodic syndrome | Not listed | Not listed | Not listed | Not listed | Not listed |
| Certolizumab pegol | Rheumatoid arthritis | Not listed | Not listed | Not listed | Not listed | Not listed |
| Denosumab | Osteoporosis, post-menopausal | Listed without PLA | Listed without PLA | Listed without PLA | Not listed | Listed without PLA |
| Eculizumab | Paroxysmal nocturnal hemoglobinuria | Not listed | Listed with PLA | PLA in place | Not listed | Not listed |
| Eltrombopag olamine | Chronic immune thrombocytopenic purpura | Under review | Under review | Not listed | Not listed | Not listed |
| Febuxostat | Gout | Listed without PLA | Listed without PLA | Listed without PLA | Not listed | Listed without PLA |
| Fingolimod | Multiple sclerosis | Not listed | Under review | Under review | Not listed | Listed without PLA |
| Golimumab | Arthritis, psoriatic, rheumatoid; ankylosing spondylitis | Listed without PLA | Listed without PLA | Listed without PLA | Listed without PLA | Listed without PLA |
| Lacosamide | Epilepsy, partial onset seizures | Listed without PLA | Listed without PLA | Listed without PLA | Not listed | Listed without PLA |
| Mometasone furoate & formoterol | Asthma | Listed without PLA | Not listed | Not listed | Not listed | Not listed |
| Paliperidone palmitate | Schizophrenia | Listed without PLA | Not listed | Not listed | Not listed | Not listed |
| Prasugrel hydrochloride | Acute coronary syndrome | Listed without PLA | Not listed | Not listed | Not listed | Not listed |
| Romiplostim | Chronic immune thrombocytopenic purpura | Not listed | Not listed | Not listed | Not listed | Not listed |
| Sapropterin dihydrochloride | Phenylketonuria | Listed without PLA | Not listed | Under review | Not listed | Not listed |
| Saxagliptin | Diabetes mellitus (type 2) | Listed without PLA | Not listed | Under review | Not listed | Not listed |
| Tadalafil | Pulmonary arterial hypertension | Listed without PLA | Not listed | Not listed | Not listed | Not listed |
| Telmisartan / Amlodipine | Hypertension | Listed without PLA | Under review | Listed without PLA | Listed without PLA | Listed without PLA |
| Ticagrelor | Acute coronary syndrome | Listed without PLA | Under review | Not listed | Not listed | Not listed |
| Tocilizumab | Rheumatoid arthritis | Listed without PLA | Listed without PLA | Listed without PLA | Not listed | Listed without PLA |
| Velaglucerase alfa | Gaucher's disease | Not listed | Not listed | Not listed | Not listed | Not listed |
Listed = Drug listed on provincial formulary with or without conditions or special authorization requirements
Funded = Drug funded on special terms but not listed on provincial formulary
a
While eculizumab is not funded, a PLA negotiated through the Pan-Canadian Purchasing Alliance is in place should government funding be provided on case-by-case basis.